EverHint – Momentum Swing — Explosive Volume Breakout for Apr 14, 2026 – 3 Signals – Healthcare Leads (2)
What This Signal Is (Quick)
Explosive Volume Breakout is a momentum swing trading strategy focused on Breakouts with 2.5x+ volume surge - institutional buying pressure.
Signal Type: Breakout (momentum continuation)
What Makes This Signal:
- Stock showing strong momentum near or at highs
- Increased volume confirms institutional interest
- Breaking out or consolidating near resistance
- Breakouts with 2.5x+ volume surge - institutional buying pressure
Ideal For: Traders seeking breakouts with exceptional volume confirmation
Key Criteria:
-
Strong RSI momentum (configurable thresholds)
-
Volume surge above average
-
Price momentum confirmation
-
Minimum ADV: $25M+ (varies by variant)
-
Earnings buffer: 7 days pre/post earnings
-
Variant-specific filters applied
Holding Period: 1-4 weeks
Risk Level: Medium-High
How We Ranked Today
Ranked by composite momentum score (higher = stronger momentum)
📊 Momentum Swing — Explosive Volume Breakout Signals (3 Total)
Ranked by score:
| Rank | Ticker | Company | Sector | Last ($) | Score | Vol Thrust | @52w | Insider Net | Days → Earnings | Est EPS | Mkt Cap ($B) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TVTX | Travere Therapeutics, ... | Healthcare | 42.13 | 0.850 | 6.83x | 0.0% | $-4.7M | 15 | $5.07 | 3.9 |
| 2 | GSAT | Globalstar, Inc. | Communication Services | 79.91 | 0.650 | 6.69x | 0.0% | — | 22 | $1.05 | 10.3 |
| 3 | AVNS | Avanos Medical, Inc. | Healthcare | 24.63 | 0.000 | 14.88x | 0.0% | — | 20 | $1.25 | 1.1 |
Field Notes
Sector concentration: Healthcare (2), Communication Services (1)
Insider selling: TVTX (Travere Therapeutics, Inc., $-4.7M)
Data coverage: 33.3% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 66.7% news
Peer Analysis
Understanding how these stocks relate to their industry peers:
TVTX (Travere Therapeutics, Inc.): Leads 10 peers: CGON ($67.28, -0.6%), TARS ($73.81, +1.6%), CELC ($120.85, +0.4%), XENE ($59.35, +1.3%), CNTA ($39.59, +0.1%) | Peer of: ARQT ($25.09, +4.0%), CELC ($120.85, +0.4%), CGON ($67.28, -0.6%) and 9 more
AVNS (Avanos Medical, Inc.): Leads 9 peers: VREX ($11.74, +2.8%), CTKB ($4.62, +0.7%), CLPT ($10.38, +3.7%), PACB ($1.57, +8.3%), CYH ($3.07, +0.3%) | Peer of: BVS ($9.91, +5.2%), CLPT ($10.38, +3.7%), CMPS ($5.75, -0.3%) and 8 more
GSAT (Globalstar, Inc.): Leads 6 peers: TKC ($6.42, +0.2%), TDS ($45.49, +0.5%), PHI ($20.65, +0.9%), LUMN ($7.80, +0.1%), MSGS ($339.74, +2.6%) | Peer of: MSGS ($339.74, +2.6%), NXST ($194.11, +5.3%), TKC ($6.42, +0.2%)
Recent Headlines
AVNS (Avanos Medical, Inc.)
- This Healthcare Stock Is Rising 69%. It's Getting Bought Out for a Big Premium. (source)
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avanos Medical, Inc. (NYSE: AVNS) (source)
- Shareholder Alert: Ademi LLP investigates whether Avanos Medical Inc. is obtaining a Fair Price for Public Shareholders (source)
- AVNS Stock Alert: Halper Sadeh LLC is Investigating Whether Avanos Medical, Inc. is Obtaining a Fair Price for its Shareholders (source)
- AIP to take Avanos Medical private in a deal valued at about $1.27 billion (source)
- Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion (source)
TVTX (Travere Therapeutics, Inc.)
- FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients (source)
- Travere Therapeutics Stock Skyrockets On FDA Approval (source)
- Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript (source)
- US FDA expands approval for Travere Therapeutics' drug for rare kidney disease (source)
- Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS (source)
- Roy Baynes Sells 10,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock (source)
- Aberdeen Group plc Trims Holdings in Travere Therapeutics, Inc. $TVTX (source)
Market Context
Broad market indices are advancing, with the Nasdaq leading gains at +1.94%, followed by the S&P 500 at +1.17% and the Dow Jones at +0.66%. This upward trend signals strong momentum and elevated risk appetite among investors, creating a favorable environment for momentum swing strategies reliant on explosive volume breakouts. The decisive broad participation supports potential follow-through in high-conviction setups, particularly as declining volatility encourages chasing breakouts without excessive fear-driven reversals.
The VIX at 18.36, down 3.97%, reflects moderating volatility, which tempers extreme intraday swings while preserving enough market movement for momentum plays to unfold. Lower VIX levels reduce the risk of whipsaws in breakout trades, allowing volume-driven surges to sustain in a risk-on climate. However, traders should monitor for any VIX rebound, as it could compress swing opportunities in this strategy.
With healthcare as the top sector amid this rotation, the bullish trend favors defensive-to-growth shifts, amplifying breakout signals in areas showing relative strength. Overall risk appetite supports aggressive positioning in momentum setups, though sector leadership underscores the need for alignment with prevailing flows to maximize edge.
Sharing Call-to-Action
💪 If this gave you insight, a quick like, share, or subscribe supports the continued work behind EverHint.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/